JAMA
Vol. 301 No. 12, pp. 1201-1304, March 25, 2009
http://jama.ama-assn.org/current.dtl

News and Analysis
Pneumonia Hospitalizations Among Young Children Before and After Introduction of Pneumococcal Conjugate Vaccine -United States, 1997-2006
JAMA. 2009;301(12):1220-1222.
[Extract: first 75 words]
Streptococcus pneumoniae is the leading bacterial cause of community-acquired pneumonia hospitalizations and an important cause of bacteremia and meningitis, especially among young children and older adults.^1-2 A 7-valent pneumococcal conjugate vaccine (PCV7) was licensed and the Advisory Committee on Immunization Practices formulated recommendations for its use in infants and children in February 2000.² Vaccination coverage rapidly increased during the second half of 2000, in part through funding by CDC’s Vaccines for Children program. Subsequently, active population- and laboratory-based surveillance demonstrated substantial reductions in invasive pneumococcal disease (IPD) among children and adults.³ In addition, decreases in hospitalizations and ambulatory-care visits for all-cause pneumonia also were reported.^4-5 To gauge whether the effects of PCV7 on reducing pneumonia continue, CDC is monitoring pneumonia hospitalizations by using data from the Nationwide Inpatient Sample. This report provides an update for 2005 and 2006, the most recent years for . . .